On November 19, Barclays released a research report on Europe's medical technology and services sector, highlighting companies with strong competitive moats, steady demand and clear earnings growth prospects, and named EssilorLuxottica as its top pick in the industry.
EssilorLuxottica: the top defensive growth choice in the sector
Barclays believes market expectations for growth in EssilorLuxottica's wearable device business have already been substantially revised down and are now at more reasonable levels. Although the company's main business is consumer-facing, its core eyewear operations possess strong competitive barriers, and demand is highly resilient to economic cycles. At present, the company's share price trades at a significant discount to the fair value assessed by Barclays.
Philips: earnings growth potential has yet to be fully priced in
Among medical device makers, Barclays is most bullish on Royal Philips NV, with its forecast for the company's adjusted earnings before interest and taxes (EBIT) coming in 6% above market consensus. The bank has growing confidence in Philips management's ability to deliver earnings growth, and sees notable differentiated competitive advantages in its patient monitoring business. Barclays notes that while medical device makers face challenges such as potential tariff increases, rising production costs and limited pricing power, industry demand remains highly resilient, with relatively low reimbursement policy and regulatory risks.
Fresenius: biosimilars business expected to drive a valuation rebound
Barclays prefers Fresenius SE over its former majority-owned subsidiary Fresenius Medical Care. The bank expects Fresenius SE to achieve steady mid-single-digit growth, with expansion in its Fresenius Kabi business expected to push group margins beyond target in the medium term. Fresenius recently struck a strategically transformative biosimilars deal that could bring in an additional 2.5 billion euros in revenue. Barclays believes this long-term growth opportunity is not yet fully reflected in the company's valuation. Currently, based on 2027 expected earnings, Fresenius SE trades at a price-to-earnings ratio of about 14 times, well below peer Sandoz's 22 times. Barclays expects the valuation gap between the two to gradually narrow.